|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MCRS1 |
Gene summary for MCRS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MCRS1 | Gene ID | 10445 |
| Gene name | microspherule protein 1 | |
| Gene Alias | ICP22BP | |
| Cytomap | 12q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96EZ8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10445 | MCRS1 | LZE4T | Human | Esophagus | ESCC | 1.17e-03 | 1.72e-01 | 0.0811 |
| 10445 | MCRS1 | LZE7T | Human | Esophagus | ESCC | 3.01e-10 | 6.09e-01 | 0.0667 |
| 10445 | MCRS1 | LZE8T | Human | Esophagus | ESCC | 2.34e-07 | 2.96e-01 | 0.067 |
| 10445 | MCRS1 | LZE20T | Human | Esophagus | ESCC | 6.92e-03 | 2.31e-01 | 0.0662 |
| 10445 | MCRS1 | LZE22D1 | Human | Esophagus | HGIN | 2.02e-02 | 1.87e-01 | 0.0595 |
| 10445 | MCRS1 | LZE22T | Human | Esophagus | ESCC | 2.96e-03 | 2.29e-01 | 0.068 |
| 10445 | MCRS1 | LZE24T | Human | Esophagus | ESCC | 9.37e-14 | 4.11e-01 | 0.0596 |
| 10445 | MCRS1 | LZE6T | Human | Esophagus | ESCC | 3.55e-06 | 3.87e-01 | 0.0845 |
| 10445 | MCRS1 | P1T-E | Human | Esophagus | ESCC | 1.25e-09 | 4.90e-01 | 0.0875 |
| 10445 | MCRS1 | P2T-E | Human | Esophagus | ESCC | 3.11e-42 | 7.01e-01 | 0.1177 |
| 10445 | MCRS1 | P4T-E | Human | Esophagus | ESCC | 4.95e-23 | 6.26e-01 | 0.1323 |
| 10445 | MCRS1 | P5T-E | Human | Esophagus | ESCC | 2.73e-10 | 1.83e-01 | 0.1327 |
| 10445 | MCRS1 | P8T-E | Human | Esophagus | ESCC | 3.59e-41 | 6.34e-01 | 0.0889 |
| 10445 | MCRS1 | P9T-E | Human | Esophagus | ESCC | 2.14e-12 | 2.82e-01 | 0.1131 |
| 10445 | MCRS1 | P10T-E | Human | Esophagus | ESCC | 1.40e-26 | 4.29e-01 | 0.116 |
| 10445 | MCRS1 | P11T-E | Human | Esophagus | ESCC | 1.43e-13 | 5.68e-01 | 0.1426 |
| 10445 | MCRS1 | P12T-E | Human | Esophagus | ESCC | 1.97e-22 | 3.90e-01 | 0.1122 |
| 10445 | MCRS1 | P15T-E | Human | Esophagus | ESCC | 2.27e-14 | 3.35e-01 | 0.1149 |
| 10445 | MCRS1 | P16T-E | Human | Esophagus | ESCC | 7.82e-39 | 5.34e-01 | 0.1153 |
| 10445 | MCRS1 | P17T-E | Human | Esophagus | ESCC | 3.54e-11 | 6.06e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001839314 | Skin | cSCC | internal peptidyl-lysine acetylation | 65/4864 | 158/18723 | 2.19e-05 | 2.54e-04 | 65 |
| GO:001657313 | Skin | cSCC | histone acetylation | 62/4864 | 152/18723 | 4.54e-05 | 4.75e-04 | 62 |
| GO:00439676 | Skin | cSCC | histone H4 acetylation | 32/4864 | 67/18723 | 1.01e-04 | 9.36e-04 | 32 |
| GO:19025703 | Skin | cSCC | protein localization to nucleolus | 11/4864 | 16/18723 | 4.08e-04 | 3.18e-03 | 11 |
| GO:0034504111 | Thyroid | PTC | protein localization to nucleus | 170/5968 | 290/18723 | 3.34e-21 | 6.38e-19 | 170 |
| GO:1903829113 | Thyroid | PTC | positive regulation of cellular protein localization | 162/5968 | 276/18723 | 2.40e-20 | 3.52e-18 | 162 |
| GO:001657010 | Thyroid | PTC | histone modification | 235/5968 | 463/18723 | 1.17e-17 | 1.15e-15 | 235 |
| GO:00064737 | Thyroid | PTC | protein acetylation | 116/5968 | 201/18723 | 3.05e-14 | 1.92e-12 | 116 |
| GO:00435437 | Thyroid | PTC | protein acylation | 134/5968 | 243/18723 | 4.22e-14 | 2.58e-12 | 134 |
| GO:00182059 | Thyroid | PTC | peptidyl-lysine modification | 188/5968 | 376/18723 | 1.34e-13 | 7.09e-12 | 188 |
| GO:1900180111 | Thyroid | PTC | regulation of protein localization to nucleus | 84/5968 | 136/18723 | 6.52e-13 | 3.08e-11 | 84 |
| GO:00183947 | Thyroid | PTC | peptidyl-lysine acetylation | 99/5968 | 169/18723 | 6.54e-13 | 3.08e-11 | 99 |
| GO:1900182110 | Thyroid | PTC | positive regulation of protein localization to nucleus | 59/5968 | 87/18723 | 6.13e-12 | 2.61e-10 | 59 |
| GO:00064757 | Thyroid | PTC | internal protein amino acid acetylation | 92/5968 | 160/18723 | 1.80e-11 | 7.06e-10 | 92 |
| GO:00183937 | Thyroid | PTC | internal peptidyl-lysine acetylation | 91/5968 | 158/18723 | 2.04e-11 | 7.91e-10 | 91 |
| GO:00165737 | Thyroid | PTC | histone acetylation | 88/5968 | 152/18723 | 2.97e-11 | 1.10e-09 | 88 |
| GO:00439677 | Thyroid | PTC | histone H4 acetylation | 45/5968 | 67/18723 | 3.16e-09 | 8.63e-08 | 45 |
| GO:00439845 | Thyroid | PTC | histone H4-K16 acetylation | 14/5968 | 20/18723 | 5.24e-04 | 3.37e-03 | 14 |
| GO:00439812 | Thyroid | PTC | histone H4-K5 acetylation | 10/5968 | 15/18723 | 5.94e-03 | 2.64e-02 | 10 |
| GO:00439822 | Thyroid | PTC | histone H4-K8 acetylation | 10/5968 | 15/18723 | 5.94e-03 | 2.64e-02 | 10 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MCRS1 | SNV | Missense_Mutation | c.928N>G | p.Arg310Gly | p.R310G | Q96EZ8 | protein_coding | deleterious(0.03) | benign(0.306) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| MCRS1 | SNV | Missense_Mutation | c.842C>G | p.Thr281Arg | p.T281R | Q96EZ8 | protein_coding | tolerated(0.06) | possibly_damaging(0.668) | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD | |
| MCRS1 | SNV | Missense_Mutation | c.676N>A | p.Glu226Lys | p.E226K | Q96EZ8 | protein_coding | deleterious(0) | possibly_damaging(0.814) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| MCRS1 | SNV | Missense_Mutation | c.556G>C | p.Glu186Gln | p.E186Q | Q96EZ8 | protein_coding | tolerated(0.47) | benign(0.007) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MCRS1 | SNV | Missense_Mutation | c.454G>A | p.Asp152Asn | p.D152N | Q96EZ8 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MCRS1 | SNV | Missense_Mutation | novel | c.1339N>C | p.Glu447Gln | p.E447Q | Q96EZ8 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| MCRS1 | SNV | Missense_Mutation | c.1091G>A | p.Gly364Asp | p.G364D | Q96EZ8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MCRS1 | SNV | Missense_Mutation | c.1245N>A | p.Phe415Leu | p.F415L | Q96EZ8 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| MCRS1 | SNV | Missense_Mutation | novel | c.908N>G | p.Asp303Gly | p.D303G | Q96EZ8 | protein_coding | deleterious(0) | benign(0.357) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
| MCRS1 | SNV | Missense_Mutation | c.287N>A | p.Arg96His | p.R96H | Q96EZ8 | protein_coding | tolerated(0.08) | probably_damaging(0.984) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |